Evidence map›Paper›PMID 9041428›Full record

ArticleJournal of clinical microbiology1997

Standardized peripheral blood mononuclear cell culture assay for zidovudine susceptibility testing of clinical human immunodeficiency virus type 1 isolates: effect of reducing the numbers of replicates and concentrations.

I C Marschner, D L Mayers, A Erice, L Smeaton, V A Johnson, D D Richman, P Reichelderfer, A J Japour

Abstract readComparative Study
In one paragraph

Article in Journal of clinical microbiology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

I C MarschnerCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA. marsch@sdac.harvard.edu
D L Mayers
A Erice
L Smeaton
V A Johnson
D D Richman
P Reichelderfer
A J Japour

Funding

WOMEN'S HEALTH AGENDAU01AI027670 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 1988 to 2006
$13.7M
BREAKTHROUGH OF HIV-1 REPLICATION DURING DRUG THERAPYR29AI032794 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JOHNSON, VICTORIA A · 1991 to 1995
–
NIAID NIH HHS AI27670NIAID NIH HHS AI32777NIAID NIH HHS AI32794
6 · The paper itself

Abstract

Zidovudine susceptibility was assessed for 525 clinical human immunodeficiency virus type 1 isolates, before and after reducing the number of replicates and zidovudine concentrations in the standardized consensus peripheral blood mononuclear cell culture assay. We conclude that omitting the 0.001 microM concentration and using duplicate rather than triplicate wells are valid and cost-effective modifications of this expensive assay.

Indexed as

Anti-HIV AgentsCells, CulturedCost-Benefit AnalysisDrug Resistance, MicrobialEvaluation Studies as TopicHIV-1HIV InfectionsHumansLeukocytes, MononuclearMicrobial Sensitivity TestsPhenotypeVirus ReplicationZidovudineAnti-HIV AgentsZidovudine

Identifiers

PMID9041428
PMCPMC229666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.